News Business Sports Entertainment Life Obituaries Opinion
Jobs Homes Cars Classifieds Shopping
Local Bloggers Cheap Tech Eco-Confessions Faceoff Furst Draft Heard on the Street Med City Movie Guy Pulse on Health Political Party

Search PB Blogs

Loading

Categories

530 posts categorized "Biobiz news"

March 03, 2014

Mayo Clinic to expand Superior Drive Support Center

Mayo Clinic is planning to expand its Superior Drive Support Center, which houses Mayo Medical Laboratories.

The clinic submitted plans on Feb. 14 to build a proposed 66,000-square-foot, two-story addition on the south side of the complex at 3050 Superior Drive N.W. 

03032014mayomedlabsMML conducts a wide variety of medical tests for hospitals worldwide. According to its website,
it performs nearly 20 million tests for more than 4,000 hospitals annually. The testing division overall has more than 3,200 employees, including more than 160 physicians and scientists. It has 58 laboratories that perform testing with support from Mayo Clinic physicians.

03032014SDSCplansWhile Mayo Clinic spokesperson confirmed the existence of site development application, officials there say it's too early to discuss specifics such as the timeline for the project or estimated cost. However, the plans designed by Flad Architects offer general details.

The expansion will more than double the lab space in the complex. It currently has 30,854 square feet of labs. The plans show that 34,000 square feet of laboratory area in the proposed addition to bring the total lab space to a total of 65,000 square feet.

Office space in the SDSC is slated to grow by 5,472 square feet, for a total of 137,000 square feet of space, following the expansion.

The remainder of the 26,000 square feet in the proposed expansion is described only as "Other." The first floor of the addition will have 28,533 square feet, and the second level will have 27,842.

Mayo Clinic moved into the 13-year-old complex in 2004. By 2011, approximately 800 employees worked at the facility. It was originally built by electronics manufacturer Celestica Inc. in 2001. When that company closed its Rochester operation, the building was left empty.

While Mayo Clinic leased the property for eight years, it purchased it for $18.5 million in August of 2012. Prior to that it was owned by 17 national investors through Triple Net Properties of Santa Ana, Calif. until they defaulted on the mortgage in 2012.  The investors bought the property for $36.8 million in 2006

When the mortgage defaulted, HSBC Bank USA took over the property. HSCB then sold it to Mayo Clinic.

While it was was originally under construction, New York City-based W. P. Carey & Co. LLC bought the complex from Celestica, which leased it back. W.P. Carey later sold it for about 70 percent more than the $21.6 million it paid for it.

December 05, 2013

Breast cancer scanner maker, once linked to Mayo Clinic, sold to Mexican company

Qg3q4q112233Here's a potentially interesting nugget of news about San Diego-based Naviscan Inc., which was at one pointed linked with Mayo Clinic through intellectual property licenses as well as direct investment by Mayo Medical Ventures.

"… Certain Naviscan Inc. assets including intellectual property and the Naviscan Trademark" have been aquired by a Mexican medical scanner company called Compañía Mexicana de Radiología or CMR.

Not sure what that means exactly, but my guess is that CMR is now behind the steering wheel at Naviscan.

Now I don't know if Mayo Clinic still has any links with Naviscan, but it certainly did at one time. I've got calls into Mayo and Naviscan to check on that.

I wrote the Mayo Clinic-Naviscan relationship back in 2005 through 2007 or so. Sheesh, I've been doing this for a long time.

From back in November 2005:

Naviscan “entered into an agreement with Mayo Foundation for Medical Education and Research (Mayo Clinic) to clinically validate and commercialize a dynamic patented molecular imaging agent for use with Positron Emission Tomography (PET) and other imaging modalities. … Mayo Clinic has licensed the vitamin B-12 molecular imaging agent technology invented by Dr. Douglas A.Collins to Naviscan PET Systems, Inc and will receive royalties from this license. Researchers at the Mayo Clinic have published studies that cancers have high uptake of radioactive B-12, especially in breast tumors."

    --------------------
"The combination of the Mayo Clinic’s patented Vitamin B-12 molecular imaging agent and Naviscan’s high-resolution PET scanner holds great promise for the future in terms of early detection of breast cancers,” said Paul Grayson, newly-appointed CEO of Naviscan PET Systems, Inc. and a Managing Director of Sanderling Ventures. “We sought out Naviscan’s technology to strategically invest in this important imaging technology platform.” Naviscan is planning clinical trial work with Mayo Clinic and other luminary sites in the U.S. to prove the value of the PEM Flex in breast cancer patients, as well as for evaluating PEM’s role with high-risk patients.”

----

From the same date in 2005:

“Naviscan PET Systems has raised a $6.5 million in Series B funding for its high resolution positron emission tomography (PET) products. The firm said that it raised the round from Sanderling Ventures, with participation from Mayo Medical Ventures."

FYI, Sanderling Ventures now leases a space in the Mayo Clinic Business Accelerator.

November 26, 2013

Mayo Clinic-linked Cardio3 part of Europe group awarded $6M research grant

C3bs_logoCardio3 BioSciences, the biotechnology firm based on Mayo Clinic research, is part of a European research consortium that recently snagged a four-year research grant for $4.5 million euros or $6 million U.S. dollars to develop "a bioresorbable polymeric valve tube for the treatment of patient suffering congenital heart defects." 

Cardio3 licensed Mayo Clinic's research back in 2007. That research is led by Mayo Clinic's Dr. Andre Terzic and Dr. Atta Behfar. The therapy uses stem cells from a patient's  bone marrow. Through a proprietary process called Cardiopoiesis, Cardio3 re-programs those cells to become heart cells. The cells are then injected back into the patient's heart to repair damaged tissue.
 
Here's some from the announcement of this latest project:

Cardio3 BioSciences…  is part of a consortium which has been awarded a highly competitive European Union Seventh Framework Programme for Research and Innovation (FP7) research grant from the European Union to support the development of a bioresorbable polymeric valve tube for the treatment of patient suffering congenital heart defects.

The project, titled "Tissue engineering of the right heart outflow tract by biofunctionalized bioresorbable polymeric valved tube", or "TEH-TUBE", is a four year project and will start on 1st January 2014.

Dorv4C3BS is part of a first-in-class, pan-European consortium composed of seven companies and universities, led by the "Assistance Publique Hopitaux de Paris (APHP)" and the team of Professor David Kalfa and Philippe Menasché.

-----

C3BS is the exploitation manager of the consortium and as such is in charge of exploiting the outcome of the research project. Within the consortium, Cardio3 is also in charge of the production of the mesenchymal stem cells and the definition and the implementation of the regulatory strategy.

-----

"We are delighted to be part of a project which represents a potential paradigm shift in the treatment of congenital cardiac diseases," said Dr. Christian Homsy, CEO of Cardio3 BioSciences. "We are also honored to be chosen by our partners to exploit the outcome of this program. It demonstrates the confidence and the recognition of our peers in the expertise we have built over the past years. FP7 grants are awarded on the basis of a highly competitive, two-stage, peer-review process, therefore this award serves as recognition of our cell production, regulatory and clinical expertise."


This wraps up a big year for Cardio3 BioSciences. It released an IPO in July on NYSE Euronext stock exchanges in Brussels and Paris that raised $29.6 million, or 23 million Euros.

November 15, 2013

Mayo Clinic to be at center of LifeScience Alley conference

This is kind of interesting. LifeScience Alley, Minnesota's medical device and bioscience industry group, is hosting its 2013 conference in Minneapolis next week.

And Mayo Clinic will be the centerpiece. If I register by midnight, it will only cost me $495 to attend. If I don't hit the button by midnight, it'll cost me $750.

Hhhhmm.... I think I'll stay in Rochester and confer with inside sources here. Maybe with the bosses gone, folks will feel more chatty than usual. Heh.

Here's some from the conference pitch:

On Wednesday, at the LifeScience Alley 2013 Conference in Minneapolis, leaders from world-class life science and healthcare organizations will discuss how changes in healthcare policy and delivery are rewriting the way our community innovates, operates and delivers value to patients.  

New-Technology-Showcase-Logo-2012-ConfOne of these organizations is this year's New Technology Showcase Partner, Mayo Clinic.  As a global leader in healthcare innovation and delivery, Mayo Clinic will be introducing several cutting-edge life science technologies, two of which originate from research conducted at Mayo.   

During the Morning Keynote, "Controlling Costs in the New Healthcare Environment - Effectively Managing the Global Supply Chain", Mayo Clinic's Karen Wolfe will highlight how the organization manages logistics and its global supply chain to minimize healthcare costs while delivering more value to its patients.   

In addition, representatives from Mayo Clinic Ventures, Mayo Clinic Research and Destination Medical Center (DMC) will be at their booths to discuss all that Mayo Clinic and the city of Rochester have to offer life science companies and entrepreneurs.

November 14, 2013

Rochester Medical shareholders OK acquisition

Rochester Medical Corp., Stewartville's largest employer, became a  subsidiary of New Jersey-based C.R. Bard at 8 a.m. today following Wednesday's overwhelmingly positive shareholder vote.

Votes representing 8.4 million shares were counted in a Minneapolis board room of the law firm Dorsey & Whitney. The $262 million deal was approved by a vote of 8.1 million in favor to 179,156 against. Another 12,054 abstained. Rochester Medical had 12.3 million outstanding shares that were eligible to vote.

Rochester Medical's Chief Financial Officer David Jonas said the vote tally took about 30 minutes. About 20 people attended the voted.

Shares of Rochester Medical were trading at $20 at the close of the market on Wednesday.

Representatives of C.R. Bard are scheduled to discuss their future plans at an all-employee meeting Friday morning at the catheter manufacturing facility. Rochester Medical has about 250 employees in Stewartville with a total of 400 worldwide.

While no specifics have been discussed about what will happen to the Stewartville facility or its employees, the president of Bard’s Medical Division made encouraging comments to staff in September.

"We are making this merger because we really believe you have got a ton to bring to us. These are additive, these two companies. There is not a ton of overlap," said Peter Curry, according to documents filed with the  U.S. Securities and Exchange Commission.

This acquisition marks the end of the local ownership of the 25-year-old company co-founded and run by CEO Anthony Conway and his brother, Vice President Philip Conway. The CEO has previously said that he and his brother will remain "deeply involved in the transition … ensuring that our new products will get to market in a very timely fashion."

November 11, 2013

Mayo Clinic, U of M startup ready for software rollout

Rochester's Evidentia Health got some press last week about its impending rollout at Fairview Health Systems.

Evidentia Health was one of the first tenants of Mayo Clinic Business Accelerator when it opened early this year.

Its billed as a health care IT company with licensed expe02272013mayoaccelerator1rtise and medical content from both Mayo Clinic and the University of Minnesota

It was co-founded by Mayo Clinic's Dr. Jeremy Friese in early 2012.Friese, an interventional radiologist, is the medical director for new ventures and business development in the Mayo Clinic's Center for Individualized Medicine.

Evidentia was profiled on Wednesday by TechdotMN, a non-profit business media group. Here's some from that piece by Yael Grauer:

As new provisions from the Affordable Healthcare Act take effect, Minnesota startup Evidentia Health is poised to help patients better understand their electronic health records (EHRs) while helping physicians meet criteria for “meaningful use” of EHR technology to improve patient care.

To receive EHR incentive pay under Medicare and Medicaid EHR Incentive Programs, healthcare providers must show they are meaningfully using EHRs by meeting various objectives.  Patients are required to be able to access their medical information within three days of when it’s created, and in 2014, this will be within one day.

The problem is that viewing EHR material and doing research online can be confusing to patients. They can jump to the wrong conclusions, worry unnecessarily and often have questions for their care team that may not be applicable.

Evidentia provides reports to both patients and physicians. The reports for patients include the most important sources of information, as well as secondary information for those interested in even more. In addition to the material in patient reports, physicians also receive recent medical research for evidence-based medicine studies.

----

Founded in October 2012, Evidentia is funded by Mayo Clinic Ventures and the University of Minnesota. A pilot program is taking place at the Family Practice Internal Medicine groups in Rochester, and Evidentia is prepared to deploy within Fairview at University Hospital.

As new provisions from the Affordable Healthcare Act take effect, Minnesota startup Evidentia Health is poised to help patients better understand their electronic health records (EHRs) while helping physicians meet criteria for “meaningful use” of EHR technology to improve patient care.

To receive EHR incentive pay under Medicare and Medicaid EHR Incentive Programs, healthcare providers must show they are meaningfully using EHRs by meeting various objectives.  Patients are required to be able to access their medical information within three days of when it’s created, and in 2014, this will be within one day.

The problem is that viewing EHR material and doing research online can be confusing to patients. They can jump to the wrong conclusions, worry unnecessarily and often have questions for their care team that may not be applicable.

Evidentia provides reports to both patients and physicians. The reports for patients include the most important sources of information, as well as secondary information for those interested in even more. In addition to the material in patient reports, physicians also receive recent medical research for evidence-based medicine studies.

“Evidentia brings together all of the information that you need to know and get it in your hands in a way that’s both credible and trustworthy, has been reviewed by physicians, and is applicable to your situation,” says CTO Brent Backhaus.

When patients access their electronic medical records, they’ve often confused about certain key phrases or conditions. Evidentia looks at the text of the reports, highlights key phrases, and presents individualized information to the patient. The information selected is both algorithmically selected and reviewed by a physician.

“We pick information to present to both to the patient and the physician that make the most sense for them to see at that point in time about their specific condition,” Backhaus says.

In addition to Backhaus, who was the founding CTO of Virtual Radiologic, Evidentia’s team includes CEO Jeremy Friese, a Harvard MBA and Associate Chair of Radiology at Mayo Clinic, and chief product officer Dan Steinberger, a U of M physician and technology leader, and founder of ProVation Medical (which had a $100m exit in 2006).

Founded in October 2012, Evidentia is funded by Mayo Clinic Ventures and the University of Minnesota. A pilot program is taking place at the Family Practice Internal Medicine groups in Rochester, and Evidentia is prepared to deploy within Fairview at University Hospital.

- See more at: http://tech.mn/news/2013/11/06/evidentia-health-mayo-clinic-ventures/#sthash.tL8tSBOX.dpuf
Yael Grauer
Yael Grauer
Yael Grauer
Yael Grauer

As new provisions from the Affordable Healthcare Act take effect, Minnesota startup Evidentia Health is poised to help patients better understand their electronic health records (EHRs) while helping physicians meet criteria for “meaningful use” of EHR technology to improve patient care.

To receive EHR incentive pay under Medicare and Medicaid EHR Incentive Programs, healthcare providers must show they are meaningfully using EHRs by meeting various objectives.  Patients are required to be able to access their medical information within three days of when it’s created, and in 2014, this will be within one day.

The problem is that viewing EHR material and doing research online can be confusing to patients. They can jump to the wrong conclusions, worry unnecessarily and often have questions for their care team that may not be applicable.

Evidentia provides reports to both patients and physicians. The reports for patients include the most important sources of information, as well as secondary information for those interested in even more. In addition to the material in patient reports, physicians also receive recent medical research for evidence-based medicine studies.

“Evidentia brings together all of the information that you need to know and get it in your hands in a way that’s both credible and trustworthy, has been reviewed by physicians, and is applicable to your situation,” says CTO Brent Backhaus.

When patients access their electronic medical records, they’ve often confused about certain key phrases or conditions. Evidentia looks at the text of the reports, highlights key phrases, and presents individualized information to the patient. The information selected is both algorithmically selected and reviewed by a physician.

“We pick information to present to both to the patient and the physician that make the most sense for them to see at that point in time about their specific condition,” Backhaus says.

In addition to Backhaus, who was the founding CTO of Virtual Radiologic, Evidentia’s team includes CEO Jeremy Friese, a Harvard MBA and Associate Chair of Radiology at Mayo Clinic, and chief product officer Dan Steinberger, a U of M physician and technology leader, and founder of ProVation Medical (which had a $100m exit in 2006).

Founded in October 2012, Evidentia is funded by Mayo Clinic Ventures and the University of Minnesota. A pilot program is taking place at the Family Practice Internal Medicine groups in Rochester, and Evidentia is prepared to deploy within Fairview at University Hospital.

- See more at: http://tech.mn/news/2013/11/06/evidentia-health-mayo-clinic-ventures/#sthash.tL8tSBOX.dpufis it will roll out its technology this year.

November 06, 2013

Mayo Clinic-linked Cardio3 Biosciences stock surges

On the record, everybody always says that competition is good. I actually suspect many of the businesses that say that don't really believe that. However, here's a concrete example of competition directly bringing in money for a company.
Cardio3 BioSciences, the Belgium biotech firm based on Mayo Clinic research, saw its stock on the NYSE Euronext stock exchanges in Brussels and Paris spike this week after a competitor, Mesoblast, got the greenlight from the FDA to start clinical trials of its C3bs_logosimiliar regenerative treatment.
Cardio3's therapy uses stem cells from a patient's  bone marrow. Through a proprietary process called Cardiopoiesis, Cardio3 re-programs those cells to become heart cells. The cells are then injected back into the patient's heart to repair damaged tissue.
As a shareholder, Mayo Clinic controls 10.44 percent of Cardio3's stock, according to Cardio3.
Here's some from a Tuesday piece by Simeon Bennett of Reuters about this week's bump.

Cardio3 advanced 50 cents to 24.50 euros at the 5:35 p.m. close of trading on Euronext Brussels, giving the Mont-Saint-Guibert-based company a market value of 155.2 million euros ($209.1 million). More than 544,000 shares were traded, 38 times the three-month daily average. The stock has surged 78 percent in the past eight trading days.

Mesoblast Ltd., an Australian company that’s using similar technology, rose to an eight-month high on Nov. 1 after saying it gained Food and Drug Administration approval to start a late-stage study with its partner, Teva Pharmaceutical Industries, of its stem cell in patients with heart failure.

That development “makes us quite confident in seeing the technology as an emerging one, and more than that, an approvable one,” Arnaud Guerin, an analyst with Portzamparc Societe de Bourse in Nantes, France, said by phone today.

October 18, 2013

Mayo Clinic decides to keep employee classifieds

Following an outcry from employees, Mayo Clinic has reversed its plans and now will keep its popular internal classified ad listings alive.

"In response to employee feedback, Mayo Clinic will launch a new, more efficient employee classifieds system on Monday, Nov. 4. The new system will be available at all locations across the institution," said Mayo spokesman Bryan Anderson.

Mayo-clinic-rochester-minnesotaMayo Clinic announced in September that it would pull the plug on its internal classified ad listings on Oct. 30, but that announcement spurred an outcry from fans of the classifieds.  
Employees have long been able to post free ads that would be seen only by other Mayo Clinic employees. The print version of the free classifieds were discontinued several years ago, but the classifieds continued to thrive on the clinic's intranet.

The Mayo ads were known as a place to find a good buy. The housing classifieds, particularly apartment or house rental ads, also were popular with Mayo Clinic's mobile workforce.

Anderson said the original decision to end them was made because the classifieds were not "a strategic imperative" and Mayo employees could use other free classifieds online.

After employees responded that they wanted to keep the classifieds, Mayo Clinic looked at its options to handle the service in "a less resource-intense way" than in the past, according to Anderson.

"The new system will be more technically sustainable and will include a large selection of categories, including ride share and research studies, to support work-related needs," he said.

October 17, 2013

IBM's Watson + Cleve Clinic and Mayo + Optum

Improving healthcare is an ongoing project, particularly here in Rochester.

Here are a couple locally linked tidbits I came across this week about efforts that are using technology to attack this issue.

IBM-Watson-Jeopardy-500x285First, everyone remembers IBM's Jeopardy-playing supercomputer Watson. Much of its development occured here in Rochester. I remember the UMR hosting a big viewing session for local business leaders and Mayo Clinic execs, so everyone could watch the celebrity computer answer Alex Trebec.

These days Watson is specializing in helping doctors at the Cleveland Clinic. They announced some developments this week.
Ibm-watson-david-ferrucci-2IBM Research unveiled two new Watson-related cognitive technologies that are expected to help physicians make more informed and accurate decisions faster and to cull new insights from electronic medical records (EMR).

The projects known as "WatsonPaths" and "Watson EMR Assistant" are the result of a year-long research collaboration with fa culty, physicians and students at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Both are key projects that will create technologies that can be leveraged by Watson to advance the technology in the domain of medicine.

• WatsonPaths explores a complex scenario and draws conclusions much like people do in real life. When presented with a medical case, WatsonPaths extracts statements based on the knowledge it has learned as a result of being trained by medical doctors and from medical literature.

WatsonPaths can use Watson's question-answering abilities to examine the scenario from many angles. The system w Watson2orks its way through chains of evidence -- pulling from reference materials, clinical guidelines and medical journals in real-time -- and draws inferences to support or refute a set of hypotheses. This ability to map medical evidence allows medical professionals to consider new factors that may help them to create additional differential diagnosis and treatment options.

----

Of course, Mayo Clinic's involved in many projects to improve medical treatments and healthcare in general.

One such project is the "strategic research alliance" Mayo Clinic formed in January with OptumHealth, a technology and consulting division of the Minnetonka, Minn.-based health insurer UnitedHealth Group.

Together they launched Optum Labs in Cambridge, Mass. Optum Labs CEO Paul Bleicher spoke about what they are doing at a conference this week.

Mayo_optum_690Optum Labs will use claims and clinical data to answer pressing health questions. It will use a database that includes 149 million patient records from UNH, electronic medical records covering 5 million lives from Mayo Clinic, and 12 million electronic medical records from Humedica.

Speaking at the recent StrataRx conference in Boston, Optum Labs CEO Paul Bleicher, M.D., Ph.D., said Cambridge, Mass.-based Optum will use advanced analytics and data visualization techniques to support research and innovation projects that will improve patient care and lower cost.

The new partnership of Mayo Clinic and OptumHealth also represents a source of new opportunities for healthcare entrepreneurs, said Bleicher, who expects new health IT companies to emerge from this effort. "That is one of the goals," Bleicher said. "We want to develop technologies and innovations that could be spun off into companies, in collaboration with venture capitalists."

He said Optum Labs is actively seeking other partners and "accepting applications from anybody doing research who is willing to do so with complete transparency, in a non-commercial fashion." The mission is "very public, publication research that will advance the cause of healthcare and anyone who participates." Influencing healthcare policymakers is also one of the goals, he said.

ViewMediaAnother priority of Optum Labs is enlisting "new partners who will bring additional data of high value," Bleicher said. "We want other payers - and everybody - to be in the tent, because if all of the data is in one place, there is opportunity to dive deep into it." It will also be important that "the findings don't stay stuck in 'silos' but are distributed widely, so they become valuable for more than just a few organizations."

The cost of some of the projects Optum Labs undertakes could be shared by National Institutes of Health grants or by partnering with life sciences or IT companies, Bleicher added.

Mark Hayward, administrator of Mayo Clinic's Center for the Science of Health Care Delivery, said there will be "information technology that will come out of our labs that will spin off new technologies and methodologies."

October 01, 2013

Cardio3 cleared to test patients in Spain

Cardio3 BioSciences, the biotechnology firm based on Mayo Clinic research, has received approval to test its regenerative heart therapy on patients in Spain.

Spain is the sixth country to clear the way for European Phase III trial of Cardo3's C-Cure. The United Kingdom, Belgium, Israel, Serbia and Hungary have all given the Belgium-based Cardio3 approval to conduct the tests of its treatment of congestive heart failure.

The company reports that 11 medical centers have already begun recruiting patients in those countries. The first patients were treated in June 2013.

"The authorization by the Spanish authorities is another important step in our development plan. We believe our unique therapy offers the potential to revolutionize treatment for heart failure, a common and severe illness," stated Cardio3 BioSciences CEO Dr. Christian Homsy in the announcement.

C3bs_logoThese tests are important in clearing the way for the revolutionary treatment to make its way to the public. The therapy uses stem cells from a patient's  bone marrow. Through a proprietary process called Cardiopoiesis, Cardio3 re-programs those cells to become heart cells. The cells are then injected back into the patient's heart to repair damaged tissue.

The potential for patients, the company as well as Mayo Clinic is huge.

It's estimated that about 23 million people worldwide are afflicted with congestive heart failure and 2 million new cases are diagnosed each year worldwide. It is a disorder on the increase in the U.S., in particular. Analysts have estimated a successful treatment for congestive heart failure could bring in about $1 billion a year for whatever company that brings it to market.

Home_productsCardio3 licensed Mayo Clinic's research in 2007. That research is led by Mayo Clinic's Dr. Andre Terzic and Dr. Atta Behfar. The company lists Mayo Clinic as controlling 25 percent of the company's capitalization.

While no royalties have accrued yet, Cardio3 says Mayo Clinic has rights to receive future royalties, which will be shared with Drs. Terzic and Behfar.

To help fund this ambitious study, Cardio3 BioSciences released an IPO in July simultaneously on NYSE Euronext stock exchanges in Brussels and Paris that raised $29.6 million, or 23 million Euros.

Prior to the IPO, Cardio3 had raised a total of $66 million in financing since it first formed and began working in this treatment.